About this trial
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 after single and multiple ascending doses in healthy and obese participants.
Eligibility criteria
Qualifiers
Adults aged 18-65 years.
Part A: Healthy participants with BMI ≥20 kg/m² and ≤27 kg/m² at screening.
Part B: Healthy obese participants with BMI ≥30 kg/m² and ≤45 kg/m² at screening.
Stable body weight (<5% change) in the past 3 months.
Disqualifiers
History of any bariatric procedure.
Uncontrolled thyroid disease (TSH >6.0 or <0.4 mIU/L).
Abnormal liver function or clinically significant liver disease
Part A: ALT or AST ≥ ULN, or total bilirubin ≥ ULN
Trial design
Treatments tested in this trial
- HM17321
- Placebo of HM17321
Treatment groups
90 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov